Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Diseases: Page 3
FDA updates draft guidance for Alzheimer's drug development biomarkers
By
LabPulse.com staff writers
The U.S. Food and Drug Administration (FDA) has released an updated draft guidance for the use of biomarkers aimed at sponsors and pharmaceutical companies developing drugs intended to treat early Alzheimer's disease.
March 14, 2024
Bluebird Bio signs state Medicaid agreement for SCD gene therapy
By
LabPulse.com staff writers
Bluebird Bio has signed its first outcomes-based Medicaid agreement for its sickle-cell disease (SCD) gene therapy Lyfgenia with the state of Michigan.
March 11, 2024
Harvard team develops compound to combat drug-resistant bacteria
By
Matt Limb
Harvard University researchers say they have created an antibiotic that can overcome many drug-resistant infections.
March 13, 2024
Study: AI assists discovery of prostate cancer subtypes
By
Matt Limb
Prostate tumors have been found to evolve along multiple pathways, leading to two distinct disease types with “pivotal” implications for diagnosis and treatment, say scientists.
March 8, 2024
MD Anderson Cancer Center acquires cell therapy switch technologies
By
Matt Limb
The University of Texas MD Anderson Cancer Center has acquired inducible switch technologies for development in cell therapy programs from Bellicum Pharmaceuticals.
March 7, 2024
Eisai invests $15M in C2N to increase Alzheimer's test access
By
LabPulse.com staff writers
C2N Diagnostics has announced that pharmaceutical company Eisai has agreed to invest up to $15 million in C2N to provide broader access to Alzheimer’s disease tests.
March 6, 2024
New class of broad-spectrum antivirals could be first line of pandemic defense: Study
By
Nick Paul Taylor
Targeting a cellular pathway has inhibited SARS-CoV-2 and other RNA viruses in preclinical tests, pointing to a potential new class of first-line antivirals with broad effectiveness against emerging pathogens.
March 5, 2024
Boston Scientific gets FDA approval for drug-coated balloon catheter
By
LabPulse.com staff writers
Boston Scientific has received U.S. Food and Drug Administration (FDA) approval for its Agent drug-coated balloon, a paclitaxel-coated balloon catheter sized to fit within blocked or constricted coronary arteries to treat coronary in-stent restenosis.
March 4, 2024
BioMĂ©rieux, FDA to collaborate on combating food-borne pathogens
By
LabPulse.com staff writers
BioMĂ©rieux has entered into a strategic research collaboration with the U.S. Food and Drug Administration (FDA) to develop technologies to improve the detection and characterization of food-borne pathogens.
March 1, 2024
Alzheimer’s study results show correlation between blood-based biomarkers and amyloid plaques
By
LabPulse.com staff writers
The first results from the Bio-Hermes study have been released, showing a strong correlation between several blood-based and digital biomarkers with the presence of amyloid plaques in the brain, a diagnostic hallmark of Alzheimer's disease (AD).
March 1, 2024
MD Anderson Cancer Center, C-Biomex collaborate on CA9-targeting radioligand
By
Matt Limb
The University of Texas MD Anderson Cancer Center has signed an agreement with South Korean company C-Biomex to co-develop CBT-001, a radioligand targeting the CA9 cancer biomarker.
February 29, 2024
Reversible, multiplex CRISPR system enhances efficacy of CAR-T cell therapy
By
Nick Paul Taylor
A CRISPR system that uses Cas13d to make reversible changes to the expression of multiple genes could overcome limitations that are holding back CAR-T cell therapies, a paper published in Cell suggests.
February 28, 2024
Previous Page
Page 3 of 283
Next Page
